Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
Ezra E.W. Cohen(Moores Cancer Center), J.-P. Machiels(Cliniques Universitaires Saint-Luc), Xiuyu Julie Cong(Boehringer Ingelheim (United States)), Jan B. Vermorken(University of Antwerp), J. Guigay(Centre Antoine Lacassagne), Makoto Tahara(National Cancer Center Hospital East), Marco Merlano(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Barbara Burtness(Yale University), Jérôme Fayette(Université Claude Bernard Lyon 1), Thomas Gauler, Paul M. Clément(Universitair Ziekenhuis Leuven), Nicole Krämer(Boehringer Ingelheim (Germany)), Flavio Solca(Boehringer Ingelheim (Austria)), Robert I. Haddad(Georgetown University), Lionnel Geoffrois(Institut de Cancérologie de Lorraine), E. Ehrnrooth(Boehringer Ingelheim (Germany)), J.M. del Campo(Vall d'Hebron Hospital Universitari), Nicholas Dupuis(North Central College), Juan J. Grau(Hospital Clínic de Barcelona), Neil Gibson(Boehringer Ingelheim (Germany)), Lisa Licitra(University of Milan), Audrey Mailliez(Centre Oscar Lambret)
Cited by 80
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926